Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus capecitabine versus trastuzumab plus capecitabine in HER2-positive metastatic breast cancer
2008-000673-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in HER2-enriched breast cancer (HER2+) comparing Lapatinib plus capecitabine with Trastuzumab plus capecitabine (2 arms). Primary endpoint: Incidence of CNS as site of first relapse. Started Nov 2008; status: completed.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2008-000673-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000673-38.